MedPath

Clinical Trial News

FDA Grants Fast Track Designation for Remestemcel-L in the Treatment of ...

Mesoblast Limited received FDA Fast Track designation for remestemcel-L to treat COVID-19 induced ARDS, aiming to expedite therapy development. A Phase 3 trial is ongoing, with promising results from a pilot study showing 75% of ventilator-dependent patients discharged after treatment. Mesoblast collaborates with Novartis for remestemcel-L's development.

Gout drug Colchicine to be tested as COVID-19 treatment | Daily Mail Online

Colchicine, a gout treatment, is being tested in the RECOVERY trial for COVID-19 due to its anti-inflammatory effects. The trial, led by Oxford University, aims to determine if colchicine can reduce death risk in hospitalized patients. It's part of the world's largest COVID-19 treatment trial, which previously found dexamethasone effective for severe cases.

Significant Improvement in Progression-Free Survival with SARCLISA Combination Therapy for Previously Treated Multiple Myeloma

A Phase 3 trial reveals that patients with previously treated multiple myeloma who stopped responding to Revlimid experienced a median progression-free survival of 41.7 months with SARCLISA combined with Kyprolis and dexamethasone, compared to 20.8 months with Kyprolis and dexamethasone alone.

FDA Grants Fast Track Designation to Panitumumab for Metastatic Colorectal Cancer Treatment

Amgen and Abgenix announced that the FDA has granted fast track designation to panitumumab, an experimental fully human monoclonal antibody, for treating metastatic colorectal cancer in patients who have failed standard chemotherapy. This designation aims to expedite the review process, potentially bringing a new treatment option to patients sooner.

FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN ...

BLINCYTO® (blinatumomab) approved by FDA for CD19-positive B-ALL treatment in consolidation phase, showing 58% reduced death risk and superior overall survival versus chemotherapy alone, based on Phase 3 E1910 trial results.

FDA just authorized a breakthrough coronavirus drug that’s proven to save lives

The FDA authorized Eli Lilly's bamlanivimab, a monoclonal antibody drug, for mild-to-moderate COVID-19 treatment. It blocks the virus from infecting cells and is most effective when administered early. Not for hospitalized patients. Administered intravenously, it aims to prevent severe complications and reduce death risk.

PSMA PET-CT Accurately Detects Prostate Cancer Spread

The FDA approved Ga-68 PSMA-11 for PET imaging in prostate cancer, enhancing detection of metastases. A trial showed PSMA PET-CT more accurately detects metastases than standard CT and bone scans, influencing treatment strategies. Despite its higher accuracy and lower radiation, PSMA PET-CT's broader use and cost implications remain under study.

Updated Safety and Efficacy Results from a Phase 2 Study of ...

The AVO triplet (acalabrutinib, venetoclax, obinutuzumab) shows high efficacy in untreated CLL patients, including those with TP53 aberrant disease, achieving 78% BM-uMRD after 15 months. With a favorable safety profile and no progression observed, it's under phase 3 trial for potential new frontline therapy.

Exploring Immunotherapy as a Potential Treatment for Penile Cancer

Recent research highlights the potential of immunotherapy in treating penile cancer, a rare malignancy with a poor prognosis in advanced stages. The study focuses on the role of HPV in the disease's carcinogenesis and the ongoing clinical trials investigating immune-modifying treatments.

The worldwide clinical trial research response to the COVID-19 ...

The article highlights the unprecedented scale of COVID-19 clinical trials, with 689 trials targeting 396,366 participants. Most trials were small, focusing on treatments like antivirals and antimalarials, with few on prevention. Despite rapid initiation, many trials face recruitment challenges, risking resource waste. Coordination and evidence-based research are urgently needed to address global health threats effectively.
© Copyright 2025. All Rights Reserved by MedPath